Pediatrics
Pediatrics
Audio Summaries
The literature in pediatrics doesn't slow down, and the papers you skip might be the ones that change your practice. OSLR turns the journals you'd read if you had the time into 3-minute audio summaries. Listen on your commute, between cases, whenever.
Journals in Pediatrics
Active journals with audio summaries available on OSLR.
American journal of respiratory and critical care medicine
Archives of disease in childhood
Arthritis & Rheumatology
Arthritis & rheumatology (Hoboken, N.J.)
Blood
British journal of sports medicine
Child abuse & neglect
Circulation
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
Clinical journal of sport medicine : official journal of the Canadian Academy of Sport Medicine
Critical care medicine
Developmental medicine and child neurology
European heart journal
Gastroenterology
Gut
Hepatology (Baltimore, Md.)
Hormone research in paediatrics
Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Journal of clinical sleep medicine : JCSM : official publication of the American Academy of Sleep Medicine
Journal of developmental and behavioral pediatrics : JDBP
Journal of hepatology
Journal of medical toxicology : official journal of the American College of Medical Toxicology
Journal of palliative medicine
Journal of pediatric gastroenterology and nutrition
Journal of perinatology : official journal of the California Perinatal Association
Journal of the American College of Cardiology
Journal of the American Society of Nephrology : JASN
Obesity (Silver Spring, Md.)
Pediatric blood & cancer
Pediatric cardiology
Pediatric critical care medicine : a journal of the Society of Critical Care Medicine and the World Federation of Pediatric Intensive and Critical Care Societies
Pediatric emergency care
Pediatric nephrology (Berlin, Germany)
Pediatric obesity
Pediatric pulmonology
Pediatric rheumatology online journal
Pediatrics
Sleep
The American journal of clinical nutrition
The American journal of sports medicine
The Journal of adolescent health : official publication of the Society for Adolescent Medicine
The Journal of allergy and clinical immunology
The Journal of clinical endocrinology and metabolism
The New England journal of medicine
The Pediatric infectious disease journal
Recent summaries
The latest articles summarized from pediatrics journals.
Alectinib as Neoadjuvant Treatment in Potentially Resectable Stage III Anaplastic Lymphoma Kinase-Positive Non-Small Cell Lung Cancer: ALNEO Phase II Trial (GOIRC-01-2020-ML42316).
The ALNEO phase II trial asked whether 8 weeks of neoadjuvant alectinib followed by surgery and adjuvant alectinib is active and feasible in treatment-naïve, potentially resectable stage III ALK-positive NSCLC. In 33 patients, the major pathologic response rate was 42% (primary endpoint, 95% CI 26-61%), with 12% achieving pathologic complete response and 85% proceeding to surgery, 86% of whom had R0 resection. Grade ≥3 adverse events occurred in 9% during neoadjuvant treatment and 27% during adjuvant therapy, supporting perioperative alectinib as a feasible and active strategy, though median survival endpoints were not yet reached.
Effect of a Multidisciplinary Intervention on Fatigue in Lymphoma Survivors With Persistent Fatigue: A Randomized Controlled Trial (the REFUEL trial).
This randomized controlled trial (REFUEL) asked whether a 12-week multidisciplinary program combining patient education, exercise, cognitive-behavioral therapy, and nutritional counseling could reduce persistent fatigue in 150 lymphoma survivors compared with usual care. The intervention significantly lowered Chalder Fatigue Questionnaire scores at 3 months (between-group difference -3.5), with the benefit persisting at 6 months but no longer significant at 9 months. It also improved physical, role, and global quality of life at 3 months, though effects on social, emotional, and cognitive functioning were not significant.
Reach of State-Mandated Insurance Coverage for Fertility Preservation in Patients With Cancer.
This retrospective cohort study of 903 patients newly diagnosed with cancer at a NCI-designated center asked how many young patients are actually reached by California's state fertility preservation insurance mandate and whether social determinants of health predict eligibility. Only 18% were eligible, with most ineligibility driven by Medicaid coverage and ineligible commercial plans, and non-English-speaking patients were significantly less likely to be eligible (adjusted RR 0.36). The authors also found that insurers often inaccurately reported lacking coverage (28% of the time) and that benefit verification took a median of 45 minutes, concluding that the mandate excludes most at-risk patients and perpetuates disparities.
Post-Menarcheal Height Gain After Gonadotropin-Releasing Hormone Agonist Treatment in Girls with Central Precocious Puberty.
This retrospective study of 66 girls with central precocious puberty treated with GnRH agonists examined how much height they gained after menarche and whether timing and skeletal maturity affected this residual growth. Post-menarcheal height gain averaged 5.55 cm and was lower when menarche occurred longer after treatment discontinuation, when menarche came at an older age or at greater height, and when bone age was advanced (>11 years) at treatment start. These findings can help clinicians counsel families about expected menarcheal timing and remaining growth after stopping GnRHa therapy.
JUVENILE IDIOPATHIC ARTHRITIS IN CHILDREN WITH TYPE 1 DIABETES: IMPACT OF CURRENT MEDICAL TREATMENT OPTIONS ON ANTHROPOMETRY AND METABOLIC CONTROL.
This study used Diabetes Patient Follow-up (DPV) registry data from 1995 to 2023 to ask whether children with both type 1 diabetes and juvenile idiopathic arthritis differ in anthropometric, metabolic, and cardiovascular risk profiles from children with type 1 diabetes alone. Comparing 489 children with both conditions to 67,462 with type 1 diabetes only, the authors found that the dual-diagnosis group used insulin pumps, CGM, and automated insulin delivery more often and achieved similar HbA1c levels, with HbA1c improving and BMI and height approaching those of the comparison group in 2020–2023. The authors conclude that glycemic control is comparable despite greater disease burden, but the elevated cardiometabolic risks support the need for tailored, interdisciplinary care.
Acute pulmonary embolism: long-term cause-specific mortality in a Chinese nationwide registry.
This nationwide Chinese registry study of 66,192 hospitalised acute pulmonary embolism patients asked how and why patients die over the long term. At 60 months, cumulative all-cause mortality was 22.4%, with cardiovascular causes (11.8%) and non-cardiovascular causes (10.6%) contributing nearly equally, and the leading causes shifted over time from acute PE and ischaemic heart disease early on to malignancy at 1-3 months and ischaemic heart disease thereafter. Exploratory analyses linked older age, residence in Western China, and abnormal vital signs to higher mortality, supporting the need for risk-adapted long-term follow-up strategies.
Lipid-Lowering Strategies in the Era of Early Atherosclerosis Detection: 2026 ACC Scientific Statement: A Report of the American College of Cardiology.
This ACC Scientific Statement asks whether lipid-lowering should begin earlier and continue longer, based on the idea that ASCVD develops from cumulative LDL cholesterol exposure over a lifetime. The authors review epidemiologic, genetic, imaging, and trial evidence, concluding that greater and longer-lasting LDL reduction lowers events, though direct evidence in younger, low-short-term-risk adults is limited. They recommend individualized, shared decision-making that integrates short- and long-term risk, risk enhancers, and, when appropriate, subclinical atherosclerosis imaging, while noting that screening thresholds, safety, adherence, and cost-effectiveness still require study.
Glucagon-Like Peptide-1 Agonists or Tezepelumab for Obesity-Associated Asthma: A Cohort Study.
This retrospective multi-institutional cohort study asked whether GLP-1-based medications (liraglutide, semaglutide, tirzepatide) offer respiratory benefits and weight loss comparable to the biologic tezepelumab in adults with obesity-associated, moderate-to-severe asthma without diabetes. Among 2,779 patients, tirzepatide initiators had a lower hazard of severe exacerbation than tezepelumab initiators (weighted HR 0.41), while semaglutide showed a similar hazard (weighted HR 0.99), and both tirzepatide and semaglutide led to faster >10% BMI reduction, less rescue inhaler use, and fewer respiratory encounters. The authors conclude that GLP-1-based therapies, particularly dual GLP-1/GIP agonists, may be comparable to biologic therapy in this population, though the observational design means randomized trials are needed to confirm these findings.
Definition and classification of cerebral palsy operationalized by the Surveillance of Cerebral Palsy in Europe.
This review traces the history of defining and classifying cerebral palsy (CP), with a focus on European harmonization efforts since 2000. The authors describe how the Surveillance of Cerebral Palsy in Europe (SCPE) developed and validated a concept and instruments for consistent diagnosis, subtyping, motor function, and associated impairments to enable reliable cross-regional comparisons. They report broad uptake of this framework, including in low- and middle-income countries, and argue that standardized operational definitions and a shared language are essential for valid CP description.
Checkpoint Inhibition during primary hepatitis E virus infection alters memory development of virus-specific T-cells in humans.
This study asks how PD-1 blockade during a primary hepatitis E virus (HEV) infection shapes the expansion and memory fate of de novo virus-specific CD8+ T-cells in humans. Comparing patients receiving immune checkpoint inhibitors with untreated patients, the authors found that treated patients' HEV-specific CD8+ T-cells showed enhanced expansion, cytotoxicity, and terminal differentiation, retaining a cytotoxic program and long-lived effector-like features rather than forming classical memory subsets. Although these cells persisted for over two years, their functional recall responses were diminished, suggesting PD-1 signaling during primary priming regulates antiviral CD8+ T-cell memory fate with implications for viral infection, vaccination, and immunotherapy.
